Efficacy of Amitriptyline for Treatment of Somatoform Pain Disorder in the Orofacial Region: A Case Series

Aims: To determine the efficacy of amitriptyline and the optimal dosage for treating a somatoform pain disorder in the orofacial region. Methods: Thirty outpatients with orofacial pain who ful-filled the criteria of pain disorder were recruited for the study. Twenty-three patients had specific precipitating events in their past history, which they considered to be the origin of the pain. Amitriptyline was administered and the dose was gradually increased up to a daily dose of 250 mg. The response to treatment was evaluated using a numeric rating scale and the Clinical Global Impression Scales. Results: Five patients dropped out and 25 patients (83%) completed the trial. Twenty-two patients became pain free or nearly pain free, while 3 patients who also completed the study did not respond at all, even though they took a daily dose of 250 mg amitriptyline. For responders, the mean daily dose of amitriptyline was 77.5 ± 51.5 mg (range, 10 to 200 mg). Four patients (16%) obtained pain relief with a daily dose of less than 50 mg, while 3 patients (12%) needed a daily dose of 150 mg or more for pain relief. Adverse side effects were observed in 19 patients. Conclusion: Amitriptyline was effective in relieving pain associated with a somatoform pain disorder in the orofacial region. The dose of amitriptyline may need to be as high as that used to treat a major depression.

orofacial pain; pain disorders; amitriptyline; tricyclic antidepressants (TCAs); precipitating event

1. Coulthard P, Morris S, Hamilton AJ. Unexplained physical symptoms in dental patients. Br Dent J 1998;184:378–382.

2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, ed 4, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000:498–503.

3. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.

4. Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences, Clinical Psychiatry, ed 7. Baltimore, MD: Williams & Wilkins, 1994:618.

5. Fishbain DA. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med 1998;60:503–509.

6. Dionne RA. Antidepressants for chronic orofacial pain. Compend Contin Educ Dent 2000;21:822–828.

7. Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain 1987;31:199–209.

8. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990;10:262–270.

9. McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992;47:646–652.

10. Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: The gain is modest. Pain 1990;42:35–42.

11. Pettengill CA, Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. Cranio 1997;15:53–56.

12. Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield CA. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: A survey. Clin J Pain 1997;13:324–329.

13. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: Presentation and treatment. Br Med J (Clin Res Ed) 1984;288:436–438.

14. Feinmann C, Harris M. Psychogenic facial pain. Part 1: The clinical presentation. Br Dent J 1984;156:165–168.

15. Feinmann C, Harris M. Psychogenic facial pain. Part 2: Management and prognosis. Br Dent J 1984;156: 205–208.

16. Guy W. Clinical Global Impressions (CGI). In: Early Clinical Drug Evaluation Unit Assessment Manual for Psychopharmacology, revised ed. Washington, DC: Department of Health, Education, and Welfare, 1976.

17. Sadock BJ, Sadock VA, Harold I. Kaplan and Sadock’s Pocket Handbook of Psychiatric Drug Treatment, ed 3. Philadelphia: Lippincott Williams & Wilkins, 2001:250–251.

18. Harris MH. Psychogenic facial pain. Int J Oral Surg 1981;10:183–186.

19. Reik L Jr. Atypical odontalgia: A localized form of atypical facial pain. Headache 1984;24:222–224.

20. Bates RE Jr, Stewart CM. Atypical odontalgia—Phantom tooth pain. Oral Surg Oral Med Oral Pathol 1991;72:479–483.

21. Pertes RA, Bailey DR, Milone AS. Atypical odontalgia: A nondental toothache. J N J Dent Assoc 1995;66:29–31, 33.

22. Melis M, Lobo SL, Ceneviz C, et al. Atypical odontalgia: A review of the literature. Headache 2003;43:1060–1074.

23. Zitman FG, Linssen AC, Edelbroek PM, Van Kempen GM. Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? Pain 1991;47:25–30.

24. Rees RT, Harris M. Atypical odontalgia. Br J Oral Surg 1978;16:212–218.

25. Graff-Radford SB, Solberg WK. Atypical odontalgia. J Craniomandib Disord 1992;6:260–265.

26. Votta TJ, Mandel L. Somatoform salivary complaints: Case reports. N Y State Dent J 2002;68:22–26.

27. The American Academy of Orofacial Pain. Okeson JP (ed). Orofacial Pain: Guidelines for Assessment, Classification, and Management. Chicago: Quintessence, 1996:214–215.

28. Vickers ER, Cousins MJ, Walker S, Chisholm K. Analysis of 50 patients with atypical odontalgia: A preliminary report on pharmacological procedures for diagnosis and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:24–32.

29. Okeson JP. Bell’s Orofacial Pains, ed 5. Chicago: Quintessence, 1995.

30. Votta TJ, Mandel L. Somatoform salivary complaints: Case reports. N Y State Dent J 2002;68:22–26.

31. Lingjaerde O, Ahlfors UG, Bech P, Denker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):7S–100S.